GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Revenue per Share

Rosetta Genomics (Rosetta Genomics) Revenue per Share : $2.70 (TTM As of Jun. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Revenue per Share?

Rosetta Genomics's revenue per share for the three months ended in Jun. 2017 was $0.34. Rosetta Genomics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2017 was $2.70.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Rosetta Genomics's Revenue per Share or its related term are showing as below:

ROSGQ's 3-Year Revenue Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 6
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Rosetta Genomics Revenue per Share Historical Data

The historical data trend for Rosetta Genomics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Revenue per Share Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.51 1.42 6.57 5.30

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 0.23 1.27 1.10 0.34

Competitive Comparison of Rosetta Genomics's Revenue per Share

For the Diagnostics & Research subindustry, Rosetta Genomics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's PS Ratio falls into.



Rosetta Genomics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Rosetta Genomics's Revenue Per Share for the fiscal year that ended in Dec. 2016 is calculated as

Revenue Per Share (A: Dec. 2016 )=Revenue (A: Dec. 2016 )/Shares Outstanding (Diluted Average) (A: Dec. 2016 )
=9.234/1.743
=5.30

Rosetta Genomics's Revenue Per Share for the quarter that ended in Jun. 2017 is calculated as

Revenue Per Share (Q: Jun. 2017 )=Revenue (Q: Jun. 2017 )/Shares Outstanding (Diluted Average) (Q: Jun. 2017 )
=0.87/2.546
=0.34

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rosetta Genomics  (OTCPK:ROSGQ) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Rosetta Genomics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458